Saphnelo approved in the EU for the treatment of moderate to severe systemic lupus erythematosus – AstraZeneca
AstraZeneca’s Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus… read more.